Line 342: | Line 342: | ||
Human Practices group has been one of the critical parts of the project since the very beginning. Unlike experiment group, Human Practices concern more about bringing the experimental result to reality application.<br/> | Human Practices group has been one of the critical parts of the project since the very beginning. Unlike experiment group, Human Practices concern more about bringing the experimental result to reality application.<br/> | ||
<br/> | <br/> | ||
− | At the beginning of the project, HP tried to find out whether MSCs is really effective in clinical using. We interviewed patients and doctors in order to know the effect and their attitude towards MSCs therapy, the result showed that MSCs do have effectiveness but limited, which means MSCs cannot replace the regular anti-inflammatory medicine but have advantages in combination with medication. In consideration of this situation, we put up the possibility of enhancing the effectiveness of MSCs and then had a further talk with our PI.<br/> | + | At the beginning of the project, HP tried to find out whether MSCs is really effective in clinical using. We <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Interview#doctor" target="_blank">interviewed patients and doctors</a> in order to know the effect and their attitude towards MSCs therapy, the result showed that MSCs do have effectiveness but limited, which means MSCs cannot replace the regular anti-inflammatory medicine but have advantages in combination with medication. In consideration of this situation, we put up the possibility of enhancing the effectiveness of MSCs and then had <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Interview#pi" target="_blank">a further talk with our PI.</a><br/> |
− | More. | + | <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Interview" target="_blank">More</a>.<br/> |
<br/> | <br/> | ||
− | During medium phage of the project, we devote ourselves to study and investigate other aspects connected to our project including ethics, law and legislation, safety, product analysis including intellectual property rights and so on by literature studying, interview and questionnaire, attending Cell Therapy Annual Meeting etc. | + | During medium phage of the project, we devote ourselves to study and investigate other aspects connected to our project including |
+ | <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Ethics" target="_blank">ethics</a>, | ||
+ | <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Legislation" target="_blank">law and legislation</a>, | ||
+ | <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Safety" target="_blank">safety</a>, | ||
+ | <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Products" target="_blank">product analysis</a> including intellectual property rights and so on by literature studying, interview and questionnaire, attending Cell Therapy Annual Meeting etc.<br/> | ||
<br/> | <br/> | ||
− | Time flies. It is almost the end phage of the project this year, but we don't want to stop here. We can do more and better! We have done a lot of researches and had many activities during the project and we admit that there is such a large room for us to improve. We have no time to finish them in this year but we draw a discussion of Room for Improvement for the teams next year. | + | Time flies. It is almost the end phage of the project this year, but we don't want to stop here. We can do more and better! We have done a lot of researches and had many activities during the project and we admit that there is such a large room for us to improve. We have no time to finish them in this year but we draw a discussion of |
+ | <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Our_Story#improvement" target="_blank">Room for Improvement</a> for the teams next year.<br/> | ||
<br/> | <br/> | ||
− | Get more information from our story page. | + | Get more information from <a href="https://2016.igem.org/Team:SYSU-MEDICINE/Our_Story" target="_blank">our story</a> page. <br/> |
</p> | </p> |
Revision as of 11:27, 19 October 2016
Integrated Human Practices
Human Practices group has been one of the critical parts of the project since the very beginning. Unlike experiment group, Human Practices concern more about bringing the experimental result to reality application.
At the beginning of the project, HP tried to find out whether MSCs is really effective in clinical using. We interviewed patients and doctors in order to know the effect and their attitude towards MSCs therapy, the result showed that MSCs do have effectiveness but limited, which means MSCs cannot replace the regular anti-inflammatory medicine but have advantages in combination with medication. In consideration of this situation, we put up the possibility of enhancing the effectiveness of MSCs and then had a further talk with our PI.
More.
During medium phage of the project, we devote ourselves to study and investigate other aspects connected to our project including
ethics,
law and legislation,
safety,
product analysis including intellectual property rights and so on by literature studying, interview and questionnaire, attending Cell Therapy Annual Meeting etc.
Time flies. It is almost the end phage of the project this year, but we don't want to stop here. We can do more and better! We have done a lot of researches and had many activities during the project and we admit that there is such a large room for us to improve. We have no time to finish them in this year but we draw a discussion of
Room for Improvement for the teams next year.
Get more information from our story page.